Drugs Medical Pharma

Zevra Therapeutics completes acquisition of Acer in a $91m deal

Health emergencies, prevention, preparedness, and response, will top the agenda at the second Health Working Group meeting of G20 member nations during the two-day meeting starting in India today.

HQ Team

November 21, 2023: Zevra Therapeutics, Inc. has finalized its acquisition of Acer Therapeutics Inc in a $91m deal. This strategic acquisition strengthens Zevra’s commitment to developing and commercializing treatments for rare diseases.

The acquisition of Acer brings valuable assets to Zevra, including OLPRUVA®, indicated for the treatment of certain urea cycle disorders (UCDs), and EDSIVO™, currently in Phase 3 for vascular Ehlers-Danlos syndrome (vEDS). This strategic move not only enhances Zevra’s clinical portfolio but also strengthens its commercial and development capabilities with the addition of key Acer personnel and existing commercial systems.

Zevra Therapeutics president and CEO Neil McFarlane stated: “The acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community. 

“With our combined resources, expanded portfolio and expert capabilities, we have the opportunity to make a tremendous impact on the lives of people with serious rare diseases. We are excited about the opportunities ahead for patients and remain focused on executing our strategic priorities to create long-term shareholder value.”

Post the Acer transaction, Zevra has agreed to sell shares of its common stock, generating approximately $6.0 million in gross proceeds. Zevra also purchased Acer’s senior secured debt for $28.5mThe completion of this transaction is anticipated on or about November 22, 2023, pending customary closing conditions.

Zevra Therapeutics, dedicated to rare disease solutions, continues to pursue its mission by strategically expanding its portfolio and capabilities. For more information, visit www.zevra.com.

Leave a Reply

Your email address will not be published. Required fields are marked *